Evaluation of Comprehensive iron therapy using hypoxia-inducible factor stabilizer in Patients with Heart Failure: Iron Deficiency pilot trial

Not Applicable

Recruiting

• Conditions: Heart failure patients with concomitant iron failure

• Registration Number: JPRN-jRCTs051230146
• Lead Sponsor: Toyota Toshiaki

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-12-15
• Last Update Posted: 1 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1) hospitalized for heart failure
2) Iron deficiency (ferritin <100 ng/mL or transferrin saturation [TSAT] <20%)
3) Male: >13 g/dL and <15 g/dL; Female: >12 g/dL and <15 g/dL
4) 18 years of age or older
5) Written consent has been obtained from the patient

Exclusion Criteria

1) Active bleeding disorders
2) Hematopoietic tumor
3) Transfusion within 90 days prior to enrollment
4) Planned non-pharmacologic treatment for heart failure
5) Catecholamine-dependent status (via intravenous administration)
6) Pregnant women, women who wish to become pregnant during participation in the study, and breastfeeding mothers
7) Inappropriate to participate in this study by the attending physician or principal/participating investigator (e.g., life expectancy of less than 1 year)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in Short Physical Performance Battery (SPPB) total score at 3 months